Subscribe

Mayne Pharma Group Limited (MYX.AX)

AUD2.82 +0.02 (+0.71%)
AU ASX Healthcare Drug Manufacturers - General
Address 1538 Main North Road 5106
Salisbury South, SA, AU
CEO Aaron Gray
Website maynepharma.com
IPO 2007-06-29
ISIN AU000000MYX0

Explore sections of this company profile

Also trades on Australian Securities Exchange · MYX.AX (AUD) Other OTC · MAYNF (USD)
Description

Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia. The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients. Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases. Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
AUD2.82 +0.02 (+0.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
324.5K
Beta
1.03
Float Shares
69.49M
Free Float %
85.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-3.23% -0.83% -15.49% -4.76% -35.31% -22.83% -51.32% -32.58% -68.83% -92.05% -75.56%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2.82
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-0.96
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - General: +6.6%
    +5.1% Q4'25: +12.8% (vs Q4'23)
  • ✗
    EPS growth Drug Manufacturers - General: +18.2%
    +48.0% ★ Q4'25: +79.3% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +14.9% Q4'25: -4.4% (vs Q4'23)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    -5.4% Q4'25: -13.3% (vs Q4'23)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    -7.1% Q4'25: -20.5% (vs Q4'23)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    -0.6% ★ Q4'25: +0.0% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    0.98× ★ Q4'25: 1.92× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.04) × ERP
WACC = 82% × Ke + 18% × Kd (12.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 2.82
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Jun 2010
actual 		Jun 2011
actual 		Jun 2012
actual 		Jun 2013
actual 		Jun 2014
actual 		Jun 2015
actual 		Jun 2016
actual 		Jun 2017
actual 		Jun 2018
actual 		Jun 2019
actual 		Jun 2020
actual 		Jun 2021
actual 		Jun 2022
actual 		Jun 2023
actual 		Jun 2024
actual 		Jun 2025
actual 		Jun 2026
1 Rev. Ana.
1 EPS Ana. 		Jun 2027
1 Rev. Ana.
1 EPS Ana. 		Jun 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
37.04M
est: 42.43M (-12.7%)
48.77M
est: 49.65M (-1.8%)
51.08M
est: 52.68M (-3.0%)
82.26M
est: 80.18M (+2.6%)
142.18M
est: 148.84M (-4.5%)
140.32M
est: 147.32M (-4.7%)
267.28M
est: 262.33M (+1.9%)
572.60M
est: 596.79M (-4.1%)
530.31M
est: 536.55M (-1.2%)
525.21M
est: 525.23M (0.0%)
456.99M
est: 456.54M (+0.1%)
400.78M
est: 410.73M (-2.4%)
157.15M
est: 415.16M (-62.1%)
183.59M
est: 273.90M (-33.0%)
388.15M
est: 382.65M (+1.4%)
408.10M
est: 388.00M (+5.2%)
401.80M
401.80M – 401.80M
+3.6% YoY
403.60M
403.60M – 403.60M
+0.4% YoY
418.20M
418.20M – 418.20M
+3.6% YoY
EBITDA
8.70M
est: -18.29M (+147.5%)
8.06M
est: -20.98M (+138.4%)
13.37M
est: -22.26M (+160.1%)
8.93M
est: 11.87M (-24.8%)
42.24M
est: -1.30M (+3,350.4%)
31.69M
est: 26.82M (+18.2%)
73.71M
est: 21.36M (+245.1%)
201.12M
est: 120.14M (+67.4%)
-71.08M
est: 105.65M (-167.3%)
-241.16M
est: -172.48M (-39.8%)
-34.03M
est: -306.42M (+88.9%)
-182.40M
est: -149.24M (-22.2%)
-78.88M
est: -174.56M (+54.8%)
-193.80M
est: -184.25M (-5.2%)
-116.93M
est: -205.55M (+43.1%)
42.08M
est: -239.14M (+117.6%)
-173.19M
-173.19M – -173.19M
+27.6% YoY
-173.97M
-173.97M – -173.97M
-0.4% YoY
-180.26M
-180.26M – -180.26M
-3.6% YoY
EBIT
2.08M
est: -25.54M (+108.2%)
308.0K
est: -29.30M (+101.1%)
7.78M
est: -31.09M (+125.0%)
1.60M
est: 11.87M (-86.5%)
32.37M
est: -1.30M (+2,591.2%)
17.19M
est: 26.82M (-35.9%)
52.28M
est: 20.94M (+149.6%)
127.42M
est: 113.68M (+12.1%)
-150.96M
est: 103.38M (-246.0%)
-335.66M
est: -164.22M (-104.4%)
-118.59M
est: -306.14M (+61.3%)
-250.58M
est: -153.12M (-63.6%)
-134.06M
est: -179.10M (+25.1%)
-259.24M
est: -189.04M (-37.1%)
-185.39M
est: -210.90M (+12.1%)
-22.03M
est: -246.46M (+91.1%)
-241.88M
-241.88M – -241.88M
+1.9% YoY
-242.96M
-242.96M – -242.96M
-0.4% YoY
-251.75M
-251.75M – -251.75M
-3.6% YoY
Net Income
3.25M
est: 3.19M (+2.0%)
1.68M
est: 57.8K (+2,803.1%)
6.15M
est: 2.12M (+190.5%)
-2.84M
est: 9.44M (-130.1%)
21.29M
est: -5.20M (+509.6%)
7.76M
est: 20.40M (-62.0%)
37.36M
est: 14.45M (+158.5%)
88.57M
est: 85.21M (+3.9%)
-133.98M
est: 78.98M (-269.6%)
-279.20M
est: -131.92M (-111.6%)
-92.79M
est: -241.64M (+61.6%)
-208.42M
est: -104.96M (-98.6%)
-281.29M
est: -122.77M (-129.1%)
117.25M
est: -129.58M (+190.5%)
-174.23M
est: -168.62M (-3.3%)
-93.84M
est: -6.17M (-1,420.1%)
-33.71M
-33.71M – -33.71M
-446.2% YoY
-34.82M
-34.82M – -34.82M
-3.3% YoY
-25.32M
-25.32M – -25.32M
+27.3% YoY
SGA
4.88M
est: 27.93M (-82.5%)
8.09M
est: 32.05M (-74.7%)
8.53M
est: 34.00M (-74.9%)
19.50M
est: 14.31M (+36.3%)
34.78M
est: 38.05M (-8.6%)
45.13M
est: 34.38M (+31.3%)
87.80M
est: 86.47M (+1.5%)
118.07M
est: 200.28M (-41.0%)
136.93M
est: 105.29M (+30.1%)
158.62M
est: 134.82M (+17.7%)
136.03M
est: 133.54M (+1.9%)
106.74M
est: 148.55M (-28.1%)
133.42M
est: 173.75M (-23.2%)
184.00M
est: 183.39M (+0.3%)
216.72M
est: 204.60M (+5.9%)
251.40M
est: 255.45M (-1.6%)
264.54M
264.54M – 264.54M
+3.6% YoY
265.72M
265.72M – 265.72M
+0.4% YoY
275.34M
275.34M – 275.34M
+3.6% YoY
EPS
0.38
est: 0.04 (+843.0%)
0.16
est: 0.00 (+21,902.2%)
0.58
est: 0.03 (+2,077.7%)
-0.04
est: 0.01 (-357.8%)
0.69
est: 0.03 (+2,397.0%)
0.22
est: 0.38 (-42.6%)
0.95
est: 0.92 (+3.2%)
1.24
est: 1.35 (-8.4%)
-1.65
est: 0.62 (-366.7%)
-3.44
est: 0.32 (-1,181.3%)
-1.14
est: -0.09 (-1,175.3%)
-2.57
est: -0.09 (-2,606.9%)
-3.46
est: -0.43 (-709.1%)
-3.89
est: -0.56 (-600.9%)
-2.19
est: -0.49 (-346.9%)
-1.14
est: -0.08 (-1,361.5%)
-0.43
-0.43 – -0.43
-446.2% YoY
-0.44
-0.44 – -0.44
-3.3% YoY
-0.32
-0.32 – -0.32
+27.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-28 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-27 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-26 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-25 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-22 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-21 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-20 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-19 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-18 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-15 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-14 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-13 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-12 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-11 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-08 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-07 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-06 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-05 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-04 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-01 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-30 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-29 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-28 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-27 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-24 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-23 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-22 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-21 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-20 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-17 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-04-16 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
98.30M
OE per share TTM
1.24
Owner's Yield
50.41%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
43.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 30 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares International Small-Cap Equity Factor ETF ISCF 0.02% 123.4K 0.24%
2 State Street SPDR S&P International Small Cap ETF GWX 0.01% 107.1K 0.40%
3 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.00% 582.6K 0.06%
4 Avantis International Small Cap Equity ETF AVDS 0.00% 11.8K 0.30%
5 Avantis Responsible International Equity ETF AVSD 0.00% 15.5K 0.23%
6 Dimensional - International Small Cap ETF DFIS 0.00% 179.3K 0.39%
7 Avantis International Small Cap Value ETF AVDV 0.00% 298.2K 0.36%
8 Vanguard FTSE Pacific ETF VPL 0.00% 173.6K 0.07%
9 Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO 0.00% 2.7K 0.22%
10 Dimensional - International Vector Equity ETF DXIV 0.00% 1.8K 0.53%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-25.9K
Shares Outstanding
81.25M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Shawn Patrick O'Brien Advisor 1M male
Brant Schofield Executive Vice President of Corporate Development 1M male
Aaron Gray Chief Executive Officer 922.0K male
Frank Casty Executive VP, Global Head of R&D and Chief Medical Officer — —
Kimberly Parker Executive Vice President & General Counsel — female
Kurt Reyes Interim Global Head of People & Culture — male
Laura Loftus Associate General Counsel & Company Secretary — female
Thomas Duthy Manager of Investor Relations — —
Tony Ramy Executive Vice President of Women's Health — male
Brenton Walter Financial Controller — male
Daniel Moore President of DistributeRx — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General